Ignite Creation Date:
2025-12-25 @ 1:41 AM
Ignite Modification Date:
2026-05-19 @ 10:41 PM
Study NCT ID:
NCT01738594
Status:
TERMINATED
Last Update Posted:
2019-08-29
First Post:
2012-11-21
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
Sponsor:
Northwestern University
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | View |
| None | Recurrent Mycosis Fungoides/Sezary Syndrome | View |
| None | Stage I Cutaneous T-cell Non-Hodgkin Lymphoma | View |
| None | Stage IA Mycosis Fungoides/Sezary Syndrome | View |
| None | Stage IB Mycosis Fungoides/Sezary Syndrome | View |
| None | Stage II Cutaneous T-cell Non-Hodgkin Lymphoma | View |
| None | Stage IIA Mycosis Fungoides/Sezary Syndrome | View |
| None | Stage IIB Mycosis Fungoides/Sezary Syndrome | View |
| None | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | View |
| None | Stage IIIA Mycosis Fungoides/Sezary Syndrome | View |
| None | Stage IIIB Mycosis Fungoides/Sezary Syndrome | View |
| None | Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma | View |
| None | Stage IVA Mycosis Fungoides/Sezary Syndrome | View |
| None | Stage IVB Mycosis Fungoides/Sezary Syndrome | View |
Keywords: